ACRYLAMIDE, A DIETARY GLYCATED PRODUCT IMPLICATED IN INTESTINAL INFLAMMATION

Cecile Vignal, Nicolas Grossin, Madjid Djouina, Pierre Desreumaux, Eric Boulanger, Mathilde Body-Malapel Objectives: A strong body of evidence supports an environmental influence in the development of Inflammatory Bowel Diseases (IBD). Our aim was to determine the effects of acrylamide on intestinal homeostasis. Methods: C57bl6 mice received increasing doses of acrylamide in their drinking water (25; 50 and 100μg/kg/day) for 9 months. Colon was harvested and assessed for macroscopic, structural and histological modifications. Markers of intestinal barrier, inflammatory and immune responses were quantified. Results: The 3 doses of acrylamide induced structural abnormalities of the colon with a modification of intestinal permeability. Crypts depth, number of goblet cells per crypt and Muc 2 expression were higher in mice receiving acrylamide. Acrylamide induced a significant increase of myeloperoxidase activity and oxidative stress response compared to control mice. The immune response was also disturbed; with an increased expression of Th1 (TNF, IFNg) and Th2 cytokines (IL-4) and a decreased expression of Th17 cytokines (IL17f) in mice receiving acrylamide. Conclusion: Acrylamide disturbed intestinal homeostasis with architectural modifications, altered permeability, increased inflammation and mucosal immune response. More studies are now needed to evaluate the role of acrylamide in IBD.